These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 16412789

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y.
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG, de Weger RA.
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [Abstract] [Full Text] [Related]

  • 5. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 6. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K, Tabayashi T, Yamada K, Takeuchi M.
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [Abstract] [Full Text] [Related]

  • 7. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
    [Abstract] [Full Text] [Related]

  • 8. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K, Wano Y, Yamamoto S, Ikebata Y, Iwasaki H, Tsutani H, Naiki H, Ueda T.
    Anticancer Res; 1999 Mar; 19(6C):5631-4. PubMed ID: 10697631
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
    Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H.
    Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.
    Porter DL, Collins RH, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH.
    Biol Blood Marrow Transplant; 1999 Sep; 5(4):253-61. PubMed ID: 10465105
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I, Weiss L, Abdul-Hai A, Kasir J, Reich S, Slavin S.
    Cancer Res; 2005 Nov 01; 65(21):9735-40. PubMed ID: 16266994
    [Abstract] [Full Text] [Related]

  • 16. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Rahman SL, Mahendra P, Nacheva E, Sinclair P, Arno J, Marcus RE.
    Bone Marrow Transplant; 1998 May 01; 21(9):955-6. PubMed ID: 9613792
    [Abstract] [Full Text] [Related]

  • 17. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
    Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):414-21. PubMed ID: 16545725
    [Abstract] [Full Text] [Related]

  • 18. [Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
    Wiesneth M, Hertenstein B, Bunjes D, Novotny J, Stefanic M, Heinze B, Schreiner T, Kubanek B, Heimpel H, Arnold R.
    Beitr Infusionsther Transfusionsmed; 1994 Apr 01; 32():276-80. PubMed ID: 9480108
    [Abstract] [Full Text] [Related]

  • 19. Donor leukocyte infusions and graft-versus-malignancy.
    Antin JH.
    J Clin Apher; 2005 Jul 01; 20(2):113-6. PubMed ID: 15880356
    [No Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A, Samuel S, Tsirigotis P, Gesundheit B, Slavin S, Shapira MY.
    Biol Blood Marrow Transplant; 2006 Dec 01; 12(12):1295-301. PubMed ID: 17162211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.